$DCTH
Delcath Systems Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021043029 Filed on August 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q4 2020 Q2
Revenue $536.0K $510.0K $380.0K
YoY Change 41.05% -1.92% -7.32%
Cost Of Revenue $202.0K $210.0K $168.0K
YoY Change 20.24% -25.0% -2.33%
Gross Profit $334.0K $300.0K $211.0K
YoY Change 58.29% 25.0% -12.08%
Gross Profit Margin 62.31% 58.82% 55.53%
Selling, General & Admin $3.288M $4.540M $2.257M
YoY Change 45.68% 118.27% -14.93%
% of Gross Profit 984.43% 1513.33% 1069.67%
Research & Development $3.497M $2.740M $2.223M
YoY Change 57.31% 1.48% 29.7%
% of Gross Profit 1047.01% 913.33% 1053.55%
Depreciation & Amortization $38.00K $40.00K $40.00K
YoY Change -5.0% 0.0% -60.0%
% of Gross Profit 11.38% 13.33% 18.96%
Operating Expenses $6.785M $7.280M $4.480M
YoY Change 51.45% 52.3% 2.59%
Operating Profit -$6.451M -$6.980M -$4.269M
YoY Change 51.11% 53.74% 3.44%
Interest Expense -$40.00K -$20.00K -$52.00K
YoY Change -23.08% -100.12% -97.17%
% of Operating Profit
Other Income/Expense, Net $61.00K -$30.00K $50.00K
YoY Change 22.0% 4900.0%
Pretax Income -$6.430M -$7.030M -$4.280M
YoY Change 50.23% -156.29% -28.19%
Income Tax
% Of Pretax Income
Net Earnings -$6.430M -$7.030M -$4.275M
YoY Change 50.41% -156.29% -28.26%
Net Earnings / Revenue -1199.63% -1378.43% -1125.0%
Basic Earnings Per Share -$0.96 -$1.90
Diluted Earnings Per Share -$0.96 -$1.423M -$1.90
COMMON SHARES
Basic Shares Outstanding 6.681M 2.273M
Diluted Shares Outstanding 6.681M 2.273M

Balance Sheet

Concept 2021 Q2 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.27M $28.58M $16.01M
YoY Change 20.39% 185.8% 4474.29%
Cash & Equivalents $19.27M $28.58M $16.01M
Short-Term Investments
Other Short-Term Assets $2.336M $2.850M $2.170M
YoY Change 7.65% 46.91% 26.16%
Inventory $1.221M $855.0K $723.0K
Prepaid Expenses
Receivables $75.00K $57.00K $147.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $22.91M $32.34M $19.05M
YoY Change 20.22% 156.3% 546.99%
LONG-TERM ASSETS
Property, Plant & Equipment $1.361M $1.351M $864.0K
YoY Change 57.52% 83.81% 7.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.011M $2.297M $1.389M
YoY Change 44.78% 44.01% -48.38%
TOTAL ASSETS
Total Short-Term Assets $22.91M $32.34M $19.05M
Total Long-Term Assets $2.011M $2.297M $1.389M
Total Assets $24.92M $34.64M $20.44M
YoY Change 21.89% 143.7% 262.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.224M $1.774M $2.174M
YoY Change -43.7% -60.86% -79.71%
Accrued Expenses $3.621M $4.859M $5.429M
YoY Change -33.3% -30.06% -40.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $2.000M
YoY Change
Total Short-Term Liabilities $5.741M $10.04M $8.111M
YoY Change -29.22% -37.26% -74.05%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $0.00 $2.000M
YoY Change 0.0% -100.0%
Other Long-Term Liabilities $2.017M $2.520M $2.630M
YoY Change -23.31% 2055.74%
Total Long-Term Liabilities $4.017M $2.520M $4.630M
YoY Change -13.24% 3695.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.741M $10.04M $8.111M
Total Long-Term Liabilities $4.017M $2.520M $4.630M
Total Liabilities $9.758M $12.56M $12.74M
YoY Change -23.41% -38.95% -63.97%
SHAREHOLDERS EQUITY
Retained Earnings -$395.3M -$383.3M
YoY Change 6.51% 7.1%
Common Stock $60.00K $35.00K
YoY Change 5900.0% -80.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.16M $22.08M $7.702M
YoY Change
Total Liabilities & Shareholders Equity $24.92M $34.64M $20.44M
YoY Change 21.89% 143.7% 262.72%

Cashflow Statement

Concept 2021 Q2 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$6.430M -$7.030M -$4.275M
YoY Change 50.41% -156.29% -28.26%
Depreciation, Depletion And Amortization $38.00K $40.00K $40.00K
YoY Change -5.0% 0.0% -60.0%
Cash From Operating Activities -$7.099M -$4.600M -$7.850M
YoY Change -9.57% -14.34% 146.08%
INVESTING ACTIVITIES
Capital Expenditures -$78.00K -$70.00K -$40.00K
YoY Change 95.0% 250.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$78.00K -$70.00K -$40.00K
YoY Change 95.0% 250.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.00K 22.45M 19.37M
YoY Change -99.93% -112350.0% 483.43%
NET CHANGE
Cash From Operating Activities -7.099M -4.600M -7.850M
Cash From Investing Activities -78.00K -70.00K -40.00K
Cash From Financing Activities 13.00K 22.45M 19.37M
Net Change In Cash -7.164M 17.78M 11.48M
YoY Change -162.4% -428.65% 8730.77%
FREE CASH FLOW
Cash From Operating Activities -$7.099M -$4.600M -$7.850M
Capital Expenditures -$78.00K -$70.00K -$40.00K
Free Cash Flow -$7.021M -$4.530M -$7.810M
YoY Change -10.1% -15.33% 144.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y2M12D
dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P3Y10M24D
dcth Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P3Y10M24D
dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P3Y10M24D
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5741000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1754000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
263000
CY2021Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2000000
CY2021Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
61000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
46000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
82000
CY2020Q2 dcth Warrants Down Round Feature Increase Decrease In Equity Amount
WarrantsDownRoundFeatureIncreaseDecreaseInEquityAmount
55000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
509000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
495000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
387000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-81000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2072000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
450000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
525000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10035000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34635000
CY2020Q4 us-gaap Liabilities
Liabilities
12557000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
60000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
417449000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-395327000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22078000
us-gaap Gross Profit
GrossProfit
426000
us-gaap Cost Of Revenue
CostOfRevenue
246000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4573000
us-gaap Operating Expenses
OperatingExpenses
9770000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9344000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12071000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.40
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6589655
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1171994
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6589655
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1171994
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
33000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-40000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-52000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6430000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4275000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4330000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4275000
us-gaap Net Income Loss
NetIncomeLoss
-13177000
us-gaap Net Income Loss
NetIncomeLoss
-12136000
dcth Warrants Down Round Feature Increase Decrease In Equity Amount
WarrantsDownRoundFeatureIncreaseDecreaseInEquityAmount
55000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
6430000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6430000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13144000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22078000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2148000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
57000
CY2021Q1 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
2376000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2021Q2 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
17000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6430000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-61000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
15159000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000
CY2020Q1 dcth Adjustment To Additional Paid In Capital Registration Of Preferred Stock And Related Warrants
AdjustmentToAdditionalPaidInCapitalRegistrationOfPreferredStockAndRelatedWarrants
106000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6199000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-8005000
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
606000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000
CY2020Q2 dcth Issuance Of Common Stock And Warrants In Public Offering
IssuanceOfCommonStockAndWarrantsInPublicOffering
19378000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4275000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7702000
us-gaap Net Income Loss
NetIncomeLoss
-13177000
us-gaap Net Income Loss
NetIncomeLoss
-12136000
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
3774000
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
25000
dcth Restricted Stock Compensation Income Expense
RestrictedStockCompensationIncomeExpense
635000
us-gaap Depreciation
Depreciation
78000
us-gaap Depreciation
Depreciation
92000
dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
22000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2832000
us-gaap Paid In Kind Interest
PaidInKindInterest
79000
us-gaap Paid In Kind Interest
PaidInKindInterest
80000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-485000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
232000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
125000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
366000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
70000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-550000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2359000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1641000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1598000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-334000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-248000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11669000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13082000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
88000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
221000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-221000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23000
dcth Payments Related To Registration Costs
PaymentsRelatedToRegistrationCosts
106000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
19378000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2393000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2393000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19249000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6009000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9331000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19425000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16192000
us-gaap Interest Paid Net
InterestPaidNet
4000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
15000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications<span style="font-style:normal;">. Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</span></p>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19274000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28575000
CY2021Q2 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
101000
CY2020Q4 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
131000
CY2021Q2 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2020Q4 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19425000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28756000
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
517000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
435000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
704000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
420000
CY2021Q2 us-gaap Inventory Net
InventoryNet
1221000
CY2020Q4 us-gaap Inventory Net
InventoryNet
855000
CY2021Q2 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2020Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
290000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
845000
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
398000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
328000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2185000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2670000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6139000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6064000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4778000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4713000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1361000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1351000
CY2021Q2 dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
39600
us-gaap Operating Lease Cost
OperatingLeaseCost
324000
us-gaap Sublease Income
SubleaseIncome
109000
us-gaap Operating Lease Payments
OperatingLeasePayments
324000
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
109000
CY2021Q2 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2216000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
747000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
188000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
313000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
486000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3621000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5241000
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
221000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
406000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
694000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
650000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-07-16
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
892379
dcth Stock Issued During Period Shares Associated With Warrants
StockIssuedDuringPeriodSharesAssociatedWithWarrants
458661
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078499
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
15000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1611
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.67
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1091888
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.65
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
929000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
262388
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.87
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
246000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1091888
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
262388
CY2021Q2 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
1626000
CY2020Q2 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
605000
dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
3774000
dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
660000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5176000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4236687
dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
463421
dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
5.37
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3773266
CY2021Q2 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.59
CY2021Q2 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3773266
CY2021Q2 dcth Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
9.59
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3773266
CY2021Q2 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3773266
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6190076
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6794514
dcth Number Of Shares Pre Funded Penny Warrants Outstanding
NumberOfSharesPreFundedPennyWarrantsOutstanding
156000
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6511194
CY2020Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2038297
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6319622
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1054549
CY2021Q2 dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
170175
CY2020Q2 dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
234890
dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
270033
dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
117445
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6681369
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2273187
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6589655
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1171994
CY2021Q1 dcth Percentage Of Enrolled Patients
PercentageOfEnrolledPatients
0.87

Files In Submission

Name View Source Status
0001564590-21-043029-index-headers.html Edgar Link pending
0001564590-21-043029-index.html Edgar Link pending
0001564590-21-043029.txt Edgar Link pending
0001564590-21-043029-xbrl.zip Edgar Link pending
dcth-10q_20210630.htm Edgar Link pending
dcth-10q_20210630_htm.xml Edgar Link completed
dcth-20210630.xsd Edgar Link pending
dcth-20210630_cal.xml Edgar Link unprocessable
dcth-20210630_def.xml Edgar Link unprocessable
dcth-20210630_lab.xml Edgar Link unprocessable
dcth-20210630_pre.xml Edgar Link unprocessable
dcth-ex101_162.htm Edgar Link pending
dcth-ex311_7.htm Edgar Link pending
dcth-ex312_9.htm Edgar Link pending
dcth-ex321_8.htm Edgar Link pending
dcth-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending